Adverse cutaneous reactions to erlotinib;Efectos cutáneos adversos causados por erlotinib

Actas Dermo-Sifiliograficas

Volumn 99, Issue 1, 2008, Pages 54-60

  Pitarch Bort, Gerard ^a,b   Garde, J ^a   Torrijos, A ^a   Juarez A ^a   Febrer, M I ^a   Camps, C ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Acneiform; Epidermal growth factor receptor; Erlotinib; Paronychia; Seborrheic dermatitis

Indexed keywords

CLINDAMYCIN; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERYTHROMYCIN;

ACNE; ADULT; AGED; ARTICLE; BLEPHARITIS; CHEILITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; MALE; ORAL BLISTER; OVARY CANCER; PARONYCHIA; PREVALENCE; SEBORRHEIC DERMATITIS; SKIN BIOPSY; SKIN DEFECT; SKIN FISSURE; SKIN MANIFESTATION; XEROSIS;

EID: 39049138330     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(08)74615-5     Document Type: Article

References (34)

1. Ciardello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs. 2002;11:755-68.
2. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II Trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22;1201-8.
3. Kris MG, Natale RB, Herbts RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor tyrosine kinase, in symptomatic patients with non-small lung cancer: A randomized trial. JAMA. 2003;290:2149-58.
4. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238-47.
5. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003;4:397-406.
6. Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 2006;40:261-9.
7. Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004;90:566-72.
8. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84:23-6.
9. Fernández-Galar M, España A, López-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol. 2004;29:138-40.
10. Kurokawa I, Endo K, Hirabayashi M. Purpuric drug eruption possibly due to gefitinib (Iressa®). Int J Dermatol. 2005;44:167-8.
11. Pascual JC, Bañuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004;151:1111-2.
12. Walon L, Gilbeau C, Lachapelle JM. Éruptions acnéiformes induites par le cétuximab. Ann Dermatol Venereol. 2003;130:443-6.
13. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, et al. Acneiform eruption induced by epidermal growth factor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151:238-41.
14. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169-76.
15. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598-601.
16. Herrera-Acosta E, Martín-Ezquerra G, Iglesias M, Umbert P. Erupción acneiforme secundaria a cetuximab. Actas Dermosifiliogr. 2005;96:252-4.
17. Isarría JM, Alonso I, Segurado A, Ortiz J, Vanaclocha F. Reacción cutánea secundaria a tratamiento con Iressa (ZD 1839). Actas Dermosifiliogr. 2004;95:459-61.
18. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva®) tablets. Oncologist. 2005;10:461-6.
19. Hidalgo M, Siu L, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-79.
20. Clark GM, Pérez-Soler R, Siu L, Gordon A, Santabarbara P. Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol. 2003;22:196.
21. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancero f the head and neck. J Clin Oncol. 2004;22:77-85.
22. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt). 2003;17:23-8.
23. Pérez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res. 2004;10:4238S-40S.
24. King LE Jr, Gates RE, Stoscheck CM, Nanney LB. The EGF/TGF alpha receptor in the skin. J Invest Dermatol. 1990;94:164S-70S.
25. Bruno R, Mass RD, Jones C, Lu JF, Winer E. Preliminary population pharmacokinetics (PPK) and exposure-safety (E-S) relationships of erlotinib HCl in patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2003;22:205.
26. Pérez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23:5235-46.
27. Albanell J, Rojo F, Averbuch S, Feyereiskova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-24.
28. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-65.
29. Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol. 1985;85:239-45.
30. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 2005;23:165-74.
31. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol. 2003;42:345-6.
32. Dainichi T, Tanaka M, Tsuruta N, Furue M, Noda K. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology. 2003;207:324-5.
33. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-33.
34. Suh KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006;154:191-2.